Landmark Bio will serve as strategic
point-of-care manufacturing partner for Galapagos' CAR-T product
candidates in the Boston
area
WATERTOWN, Mass., Nov. 6, 2023
/PRNewswire/ -- Landmark Bio, a collective endeavor bringing
together leaders in industry, academia, and research hospitals to
accelerate development and industrialization of next-generation
genomic medicines, announced that it has signed a multi-year
strategic manufacturing agreement with Galapagos NV (Euronext &
NASDAQ: GLPG), an innovative biotech company with operations in
Europe and the U.S.
Under the terms of the agreement, Landmark Bio will perform GMP
manufacturing of clinical trial batches of Galapagos' development
programs of chimeric antigen receptor (CAR) T-cell therapies in
hematology-oncology in the Boston
metropolitan area.
The manufacturing agreement aims at implementing Galapagos'
novel decentralized CAR-T manufacturing model,
designed to enable clinicians to administer CAR T-cells within a
median of seven days of leukapheresis, thereby aiming to address
important limitations of current CAR-T treatments.
"We are excited to partner with Galapagos to support their CAR-T
clinical development programs in the U.S.," said Ran Zheng, CEO of
Landmark Bio. "This strategic manufacturing collaboration is a
testament to our expertise in cell and gene therapy manufacturing
and underscores our commitment to bring more life-saving therapies
to patients faster."
Landmark Bio's 44,000 square-foot fully integrated development
and manufacturing facility includes laboratory space for
translational research and early development, process and
analytical development, and technology innovation. The
biomanufacturing area is comprised of nine cleanrooms for cell
therapies, genome editing, viral vector, mRNA, and lipid
nanoparticle production as well as fill and finish and in-house
Quality Control (QC) testing. In addition, Landmark Bio provides
wraparound services such as drug development and regulatory
consulting, program management and other support services.
Financial terms of the agreement were not disclosed.
About Landmark Bio
Landmark Bio PBLLC, a statutory public benefit limited liability
company, or PBLLC, is a collective endeavor launched by leaders
from academia, the life sciences industry, and world-renowned
research hospitals to accelerate the development and
industrialization of novel therapeutics. Inspired by recent
advancements in cell and gene therapy, Landmark Bio was established
to remove barriers in drug development, create accessible
capability, expertise, and solutions, and offer a collaboration
platform to advance manufacturing technologies for the new
generation of medicines to come. Founding partners include
Harvard University, Massachusetts Institute of Technology (MIT), Cytiva, FUJIFILM Diosynth Biotechnologies
(FDB), and Alexandria Real Estate Equities, Inc. Other
collaborating institutions include Beth Israel Deaconess Medical
Center, Boston Children's Hospital, Mass General Brigham, and the
Dana- Farber Cancer Institute. For more information, visit
http://landmarkbio.com.
About Galapagos
We are a global biotechnology company with operations in
Europe and the U.S. dedicated to
developing transformational medicines for more years of life and
quality of life. Focusing on high unmet medical needs, we synergize
the most compelling science, technology, and collaborative
approaches to create a deep pipeline of best-in-class small
molecules, CAR-T therapies, and biologics in oncology and
immunology. With capabilities from lab to patient, including a
decentralized, point-of-care CAR-T manufacturing
network, we are committed to challenging the status quo and
delivering results for our patients, employees and shareholders.
For additional information, please visit www.glpg.com or follow us
on LinkedIn or X (formerly Twitter).
View original content to download
multimedia:https://www.prnewswire.com/news-releases/landmark-bio-signs-multi-year-agreement-to-manufacture-galapagos-oncology-car-t-cell-therapy-clinical-programs-at-the-point-of-care-301977650.html
SOURCE Landmark Bio